TFF Pharmaceuticals, Inc.
TFFP · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $1 |
| % Growth | -70.3% | 219.9% | -72.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $0 | $1 |
| % Margin | 100% | 78.4% | 31% | 82.2% |
| R&D Expenses | $2 | $3 | $4 | $3 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $6 | $5 |
| Operating Income | -$4 | -$4 | -$6 | -$5 |
| % Margin | -1,852.3% | -609.4% | -2,948.8% | -747.1% |
| Other Income/Exp. Net | $0 | -$1 | $0 | $1 |
| Pre-Tax Income | -$4 | -$4 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$4 | -$6 | -$5 |
| % Margin | -1,833.1% | -688.9% | -2,821.4% | -648.9% |
| EPS | -0.81 | -1.22 | -2.4 | -2.01 |
| % Growth | 33.6% | 49.2% | -19.4% | – |
| EPS Diluted | -0.81 | -1.22 | -2.4 | -2.01 |
| Weighted Avg Shares Out | 4 | 4 | 2 | 2 |
| Weighted Avg Shares Out Dil | 4 | 4 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$4 | -$6 | -$5 |
| % Margin | -1,852.3% | -587.8% | -2,752.4% | -713.8% |